Imaging has the potential to dramatically increase the efficiency of lead candidate selection by providing earlier and more highly predictive data compared to traditional methods. Imaging is also well suited for helping to facilitate translation between preclinical testing and the clinical evaluation of drugs. In addition, imaging methods are more easily applied in the newer, more realistic models of human disease that are becoming increasingly prevalent, such as models of invasive disease in the tissue of origin and transgenic mouse models, than traditional methods.
Non-invasive imaging capabilities assist with the detection of cancer and treatment response, even at the molecular level, in subcutaneous, orthotopic and genetically engineered tumor models. These non-invasive imaging capabilities allow data procurement while reducing the number of animals needed for a study and allowing the assessment of the time course of drug effect. Through our validated subcontractors, Charles River can also support the use of clinical imaging modalities, ensuring that treatment with your compound does not alter the interpretation of the imaging signal.
Imaging Technologies
- Magnetic Resonance Imaging (MRI)
- Micro-Computed Tomography (µCT)
- Positron Emission Tomography (PET)
- Dual-Energy X-Ray Absorptiometry (DEXA)
- Digital X-Ray
For more information on our imaging capabilities, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.
Related Information
Technical Sheet: Importance of Preclinical Imaging in Drug Discovery
Archived Webinar: Inflammation Models in Preclinical Drug Research: Traditional Endpoints to Translational Imaging (September 2010)
Archived Webinar: Magnetic Resonance Imaging Applications for Metabolic Profiling in Animal Models of CNS Disease (November 2009)
Poster Presentations